Process of making an enteral formula containing long-chain polyunsaturated fatty acids

• US 6,036,992 A
• Filed: 03/16/1999
• Issued: 03/14/2000
• Est. Priority Date: 03/28/1997
• Status: Expired due to Term

• Current Assignee: Abbott Laboratories
• Original Assignee: Abbott Laboratories
• Inventors: Ponder, Debra L., Dohnalek, Margaret H., Diodato, David V., Borror, David A.
• Primary Examiner(s): Weier, Anthony J.
• Application Number:
  US09/270,423
• Time in Patent Office: 364 Days
• Field of Search: 426/801, 426/662, 426/614, 514/580
• US Class Current: 426/662
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: Y10S 426/801 Pediatric

Abstract

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs) and a process for making such enteral compositions are described. More particularly, the invention relates to enteral compositions which provide long chain PUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially free of cholesterol and may be derived from egg yolk lipids, and thus are predominantly in a phospholipid form. The process of making such a composition provides improved organoleptic and stability properties. Enteral compositions according to this invention may be used to feed infants, particularly pre-term infants, to promote neural development and development of visual acuity, and to reduce the incidence of necrotizing enterocolitis.

Claims

1. A process for the production of an infant formula containing egg phospholipids having improved organoleptic properties comprising the steps of:

(a) forming a 2-15% by weight aqueous dispersion of egg phospholipids;

(b) subjecting said dispersion to de-aeration;

(c) combining said de-aerated dispersion with a mixture of protein, carbohydrates, vitamins and minerals, to form said infant formula; and

(d) homogenizing said infant formula.

2. The process according to claim 1 wherein said aqueous dispersion is formed at ambient temperatures.

3. The process according to claim 1 wherein said aqueous dispersion is about 3 to about 6% by weight egg phospholipids.

4. A method of using an infant formula according to claim 1 to increase the levels of arachidonic acid and docosahexaenoic acid in an infant'"'"'s blood serum, comprising administering said formula enterally to said infant.

5. A method of using an infant formula according to claim 4 wherein said egg phospholipid provides arachidonic acid in a concentration of from about 10 to about 31 mg per 100 kcals.

6. A method of using an infant formula according to claim 5 wherein said egg phospholipid provides docosahexaenoic acid in a concentration of from about 3 to about 16 mg per 100 kcals.

7. A method of using an infant formula according to claim 6 wherein said arachidonic acid and docosahexaenoic acid are present in a ratio of about 4:

1 to about 2;

1.

8. A process for the production of an enteral formula comprising egg phospholipids, said method comprising the steps of:

(a) providing egg phosphatide essentially free of cholesterol;

(b) dispersing said egg phosphatide at about at least 2 percent by weight in an aqueous phase to form a phospholipid dispersion prior to mixing said phospholipid with any other lipid component; and

(c) combining said phospholipid dispersion with slurries of other components of said enteral formula.

9. The process according to claim 8 wherein said phospholipid dispersion comprises from about 2 to about 15% by weight of said egg phospholipids.

10. The process according to claim 9 wherein said phospholipid dispersion comprises adding said egg phosphatide to water at about 20 to about 50°

C.

11. The process according to claim 8 wherein said phospholipid dispersion comprises from about 3 to about 6% by weight of said egg phospholipids.

12. The process according to claim 8 wherein said dispersing in aqueous phase comprises adding said egg phosphatide to water at less than about 50°

C.

13. The process according to claim 8 wherein said dispersing in aqueous phase comprises adding said egg phosphatide to water at about 20 to about 50°

C.

14. The process according to claim 8 wherein said phospholipid dispersion is subjected to de-aeration before combining said de-aerated phospholipid dispersion with said slurries of other components of said enteral formula.

15. A method of using an enteral formula according to claim 8 to increase the levels of w6 fatty acids and w3 fatty acids in human blood serum, comprising administering said formula enterally to said human.

16. The method of using an enteral formula according to claim 15 wherein said egg phospholipid provides w6 fatty acids in a concentration of from about 100 to about 425 mg per liter.

17. The method of using an enteral formula according to claim 16 wherein said egg phospholipid provides w3 fatty acids in a concentration of from about 40 to about 185 mg per liter.

18. The method of using an enteral formula according to claim 17 wherein said w6 fatty acids and said w3 fatty acids are present in a ratio of about 2:

1 to about 3;

1.